Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions
Lilly Drug Wins Narrow FDA Advisory Committee Backing
Executive Summary
Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.
You may also be interested in...
Expanded Lung Cancer Claim For Lilly’s Cyramza Faces US FDA Scrutiny
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.
Lilly’s Cyramza Shows Promise In First-Line NSCLC – But Not Much Room To Grow
Studied with Tarceva, Cyramza showed an ability to improve PFS in patients with EGFR-mutant tumors. But how will a two-company combo fare against Tagrisso monotherapy?
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.